Edwards Lifesciences Corp·4

Dec 9, 5:01 PM ET

Ullem Scott B. 4

4 · Edwards Lifesciences Corp · Filed Dec 9, 2025

Insider Transaction Report

Form 4
Period: 2025-12-09
Ullem Scott B.
CVP, Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-09$59.26/sh+7,700$456,27747,598 total
  • Sale

    Common Stock

    2025-12-09$84.47/sh7,700$650,41239,898 total
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2025-12-097,70039,000 total
    Exercise: $59.26From: 2020-05-08Exp: 2026-05-07Common Stock (7,700 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    266,318
Footnotes (2)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
  • [F2]This transaction was executed in multiple trades at prices ranging from $84.09 to $85.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    doc4.xmlPrimary